End of Treatment Visit Sample Clauses

End of Treatment Visit. Patients may voluntarily withdraw from the study drug at any time for any reason, and without prejudice to further treatment. In addition, patients may be withdrawn by the Investigator if they do not feel the patient is deriving clinical benefit or because the patient is experiencing unacceptable toxicity. The reasons for which a patient may be prematurely discontinued are listed in Section 5.6. The clinical trial database will capture reasons for withdrawal. Patients who withdraw or are removed from the study treatment will have an EOT visit within 7 days of the decision to discontinue study drug. Patients will undergo assessments as outlined in Table 2.
Sample 1
AutoNDA by SimpleDocs
End of Treatment Visit. You will need to return to the clinic within 10 days following the decision for you to discontinue participation in the study to have the following done: • Review of your medications and review of any symptoms or side effects that you may be experiencing or have experienced since the last visit • Xxxxx xxxxx • Physical exam including body weight and lung assessment, and assessment of your performance status • Eye exam • Routine blood and urine sample collections to check your overall health • ADA blood sample collection • Pregnancy test if you are a woman who may be able to get pregnant • ECG to check your heart • ECHO or MUGA to check your heart (only if you have a history of heart problems) • Pulmonary function tests to check your lungs • Chest X-ray to check your lungs • CT scan or MRI to assess your disease and check your lung status (only if it has been more than 6 weeks since the previous CT or MRI) • PK blood sample collection – one sample during visit • Patients with a cancer of the head or neck: a blood sample will be taken to do tests on tumor cells that may be circulating in your blood You will need to return to the clinic about 1 month (30 days) after your last dose of study medication to have the following done: Note: Depending on scheduling and when the decision is made for you to leave the study, the End of Treatment Visit and the One Month Follow-up Visit may be done on the same day. If this is the case, the assessments listed to be performed at the End of Treatment Visit will be the assessments to be conducted. • Review of your medications and review of any symptoms or side effects that you may be experiencing or have been experiencing since the last visit • Xxxxx xxxxx • Physical exam including body weight and lung assessment, and assessment of your performance status • Routine blood and urine sample collections to check your overall health • ADA blood sample collection • CT scan or MRI to assess your disease and check your lung status (only if disease progression was not shown on a previous CT or MRI) • PK blood sample collection – one sample during visit
Sample 1
End of Treatment Visit. Patients may voluntarily withdraw from the study drug at any time for any reason, and without prejudice to further treatment. In addition, patients may be withdrawn by the Investigator if they do not feel the patient is deriving clinical benefit or because the patient is experiencing unacceptable toxicity. The reasons for which a patient may be prematurely discontinued are listed in Section 5.6.2.2, Section 5.6.3.2, and Section 5.6.4.
Sample 1

Related to End of Treatment Visit

  • Xxx Treatment We have not promised you any particular tax outcome from buying or holding the Note.

  • Sale Treatment The Company has determined that the disposition of the Mortgage Loans pursuant to this Agreement will be afforded sale treatment for accounting and tax purposes;

  • Denial of Preferential Tariff Treatment The Customs Authority of the importing Party may deny a claim for preferential tariff treatment when: (a) the good does not qualify as an originating good; or (b) the importer, exporter or producer fails to comply with any of the relevant requirements of this Chapter.

  • Medical Treatment Undersigned understands that the Released Parties do not have medical personnel available at the location of the activities. Undersigned hereby grants the Released Parties permission to administer first aid or to authorize emergency medical treatment, if necessary. Undersigned understands and agrees that any such action by the Released Parties shall be subject to the terms of this agreement and release, including any liability arising from the negligence of the Released Parties when administering first aid or authorizing others to do so. Undersigned understands and agrees that the Released Parties do not assume responsibility for any injury or damage which might arise out of or in connection with such authorized emergency medical treatment.

  • Future Treatment of Unallowable Costs Unallowable Costs shall be separately determined and accounted for by Defendants, and Defendants shall not charge such Unallowable Costs directly or indirectly to any contracts with the United States or any State Medicaid program, or seek payment for such Unallowable Costs through any cost report, cost statement, information statement, or payment request submitted by Defendants or any of their subsidiaries or affiliates to the Medicare, Medicaid, TRICARE, or FEHBP Programs.

  • REIT Treatment The Company will use its reasonable efforts to enable the Company to continue to meet the requirements to qualify for taxation as a REIT under the Code for subsequent tax years that include any portion of the term of this Agreement except as otherwise determined by the Board of Directors of the Company to be in the best interests of stockholders.

  • Emergency Medical Treatment I grant the Releasees permission to authorize emergency medical treatment as they deem appropriate, and agree that such action by the Releasees shall be subject to the terms of this Agreement. I understand and agree that the Releasees assume no responsibility for any injury or damage that might result from such emergency medical treatment.

  • Substance Abuse Treatment Information Substance abuse treatment information shall be maintained in compliance with 42 C.F.R. Part 2 if the Party or subcontractor(s) are Part 2 covered programs, or if substance abuse treatment information is received from a Part 2 covered program by the Party or subcontractor(s).

  • Minimum Standard of Treatment 1. Each Party shall accord to a covered investment treatment in accordance with the customary international law minimum standard of treatment of aliens, including fair and equitable treatment and full protection and security. 2. The concepts of “fair and equitable treatment” and “full protection and security” in paragraph 1 do not require treatment in addition to or beyond that which is required by the customary international law minimum standard of treatment of aliens. 3. A breach of another provision of this Agreement, or of a separate international agreement, does not establish that there has been a breach of this Article.

  • Corporate Treatment The Board shall use its reasonable best efforts to take such actions as are necessary or appropriate to preserve the status of the Company as a partnership for U.S. federal (and applicable state and local) income tax purposes. If, however, the Board determines, in its sole discretion, for any reason (including the proposal, formally or informally, of legislation that could affect the Company’s status as a partnership for U.S. federal and/or applicable state and local income tax purposes) that it is not in the best interests of the Company to be characterized as a partnership, the Board may take whatever steps, if any, are needed to cause the Company to be or confirm that the Company will be treated as an association or as a publicly traded partnership taxable as a corporation for U.S. federal (and applicable state and local) income tax purposes, including by making an election to be taxed as a “C” corporation pursuant to the Code (a “Change in Tax Classification”), without any approval or vote of the Members required, and to make such filings, including without limitation, a Form 8832 with the Service, and to undertake such actions as required to effect such Change in Tax Classification. At the time and following any Change of Tax Classification, the Board shall have the right, without any approval or vote of the Members being required, to amend this Agreement as reasonably required to effect the Change in Tax Classification and to provide for the operations of the Company following such event. Notwithstanding anything in this Agreement to the contrary, in the event U.S. federal (and/or applicable state and local) income tax laws, rules or regulations are enacted, amended, modified or applied after the date hereof in such a manner as to require or necessitate that the Company no longer be treated as a partnership for U.S. federal (and/or applicable state and local) income tax purposes, then the first sentence of this Section 8.7 shall no longer apply.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!